CN111150066A - 防瘟疫免疫肽 - Google Patents
防瘟疫免疫肽 Download PDFInfo
- Publication number
- CN111150066A CN111150066A CN202010102301.0A CN202010102301A CN111150066A CN 111150066 A CN111150066 A CN 111150066A CN 202010102301 A CN202010102301 A CN 202010102301A CN 111150066 A CN111150066 A CN 111150066A
- Authority
- CN
- China
- Prior art keywords
- preventing
- polysaccharide
- cordyceps
- immune
- cordyceps sobolifera
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title description 4
- 150000004676 glycans Chemical class 0.000 claims abstract description 18
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 18
- 239000005017 polysaccharide Substances 0.000 claims abstract description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 16
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 15
- 241000357408 Ophiocordyceps sobolifera Species 0.000 claims abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 11
- 229930195729 fatty acid Natural products 0.000 claims abstract description 11
- 239000000194 fatty acid Substances 0.000 claims abstract description 11
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 11
- 239000002157 polynucleotide Substances 0.000 claims abstract description 11
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 10
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 10
- 229920001184 polypeptide Polymers 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 9
- 210000000952 spleen Anatomy 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 6
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 6
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- 241001625026 Cordyceps cicadae Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 230000036737 immune function Effects 0.000 abstract description 18
- 230000002708 enhancing effect Effects 0.000 abstract description 17
- 241000700605 Viruses Species 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 241000711573 Coronaviridae Species 0.000 abstract description 5
- 244000052769 pathogen Species 0.000 abstract description 5
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 241000712461 unidentified influenza virus Species 0.000 abstract description 5
- 230000009385 viral infection Effects 0.000 abstract description 5
- 206010035737 Pneumonia viral Diseases 0.000 abstract description 3
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 208000009421 viral pneumonia Diseases 0.000 abstract description 3
- 208000015220 Febrile disease Diseases 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract 1
- 239000011573 trace mineral Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000931705 Cicada Species 0.000 description 2
- 241000254137 Cicadidae Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
防瘟疫免疫肽以优质生物原料制成的特医食品，功能特征为，金蝉花多糖、脾多肽、蛋黄免疫球蛋白、多聚核苷酸、脂肪酸、微量元素、辅料为原料，具有显著增强免疫功能、预防多种流感病毒感染、抗病毒(多种流感病毒和冠状病毒)抗病原体、杀菌消炎、防治病毒性肺炎、防温疫清温、清热解毒等功能。
Description
一、技术领域：本发明属于生物类特医食品或功能食品，尤以优质的生物为原料，采用现代最先进的技术工艺加工而成的特医食品。
二、背景技术：本产品具有增强免疫力功能，预防多种流感、抗病毒(流感病、冠状病毒等)、抗病原体、杀菌消炎、防治病毒性肺炎、防温清温、清热解毒等功能。
三、发明内容：珍爱生命、科学防治病毒和流感。冠状病毒和2003年的非典以及每年冬春季流感的大流行，让人们了解到由病毒感染疾病的可怕，做好预防尤为重要。病毒疾病感染已成为人类社会必须尽快解决的大难题。因此，创新研发防治病毒和流感的新产品，具有深远而重要的社会意义和经济效益，也可造福人类。
四、原料组分：金蝉花多糖60-100千克、脾多肽20-60千克、蛋黄免疫球蛋白40-80千克、多聚核苷酸50-90千克、脂肪酸30-70千克、辅料为原料。
五、技术方案：
(一)金蝉花多糖(the golden cicadais)，金蝉花是一种寄生在蝉上麦角菌科虫生真菌的复合体。性寒、性甘、无毒。具有扶正固本、疏通风热、滋补脾肾、定经镇痛、明目透疹、滋补强壮等功效。现代药理研究表明，金蝉花具有增强免疫功能、抗病毒、防治肿瘤、减轻放化疗毒副作用、抗辐射、保护肝脏、抗疲劳、改善睡眠、解热镇痛等功能。
药理作用：1、增强免疫功能：金蝉在多糖并以虫草多糖和灰树花多糖参比试验，对小鼠进行淋巴转化试验，Ea及E玫瑰花试验、特异性免疫玫瑰试验(巨噬细胞试验、抗绵羊红细胞抗体、效价试验)。结果表明，金蝉花多糖具有明显的增强免疫功能作用。
2、解热镇痛：金蝉花多糖对正常及人工致热大鼠在用药后2小时内均有明显的降温作用。用扭体和热板法实验结果显示，金蝉花多糖对小鼠化学及热灼刺激性疼痛均有非常显著的镇痛抑制作用。
3、补虚、术后康复作用：最新临床研究显示，金蝉花多糖具有扶正固本、提高免疫力功能等作用，增强机体抵抗力。各种严重疾病在生病期间消耗了大量的营养物质，此时服用金蝉花多糖补充机体急需的营养，恢复体力和精力，对修复体质和对身体康复具有很好的作用。
(二)脾多肽(lienalpoiypeptide)，脾多肽是动物脾脏提取制成的一种生物多肽。主要含有多肽、游离氨基酸、核酸、总糖，可用于原发性性和继发性免疫缺陷病、呼吸道及肺部感染，在治疗放化疗引起的白细胞减少症、白血病再生性障碍贫血、恶性肿瘤、改善肿瘤恶变质、改善术后和重症患者身体恢复的辅助作用。
生物活性作用：1、增强免疫功能：临床研究证明，脾多肽对机体免疫机能有双向调节作用，能纠正机体免疫功能紊乱，具有激活和增强机体非特异性免疫功能作用，能促进T淋巴细胞，从而提高淋巴细胞免疫功能，触发和增强机体对感染的抵抗力，还可诱性生干扰素直接阻止病毒蛋白的合成与复制，并能增强细胞表面抗原表达，促进NK细胞毒活性，调节淋巴细胞和吞噬细胞功能，可明显改善机体细胞免疫功能。另外，脾多肽还具有保护肝脏的作用。
(三)、蛋黄免疫球蛋白(lmmunoglobcllin yolk，lgy)，是存在于蛋黄中的一种生物活性免疫球蛋白化合物。现代医学研究表明，蛋黄免疫球蛋白具有增强免疫功能、抗微生物病原体、消炎杀菌、抗病毒、抗肿瘤等活性作用。
生物活性功能：1、实验显示，蛋黄免疫球蛋白可使脾脏细胞杀伤细胞的活性显著上升，在中性白细胞、单核细胞/小吞噬细胞、淋巴细胞等多种免疫细胞表面存在蛋黄免疫球蛋白接受器，在血清中含有蛋黄免疫球蛋白时，就可导致中性粒细胞释放。无论是在体内或试管内，均证实具有显著的促进中性粒细胞和吞噬作用，促进自然杀伤细胞的活性，具有明显调节免疫功能作用。杀菌抗病毒：蛋黄免疫球蛋白主要的作用是于抗原起免疫反应，生成抗原与抗体复合物，从而阻断病原体对机体的危害，使病原体失去致病作用。临床验证，蛋黄免疫球蛋白与抗原结合后，能激活补体，具有非常强烈的杀菌与抗病毒能力，具有非特异性的杀伤功能，在抗病菌感染的非特异性免疫中发挥重要作用。其次，蛋白免疫球蛋白可用作急性预防和治疗剂，可中和病毒进而阻止病毒吸附和侵入细胞。用蛋黄免疫球蛋白对小鼠进行抗冠状病毒和抗流感病毒紧急预防实验，结果显示，对高致病性冠状病毒和流感病毒特异性免疫具有保护效果，具有显著的作用。
(四)多聚核苷酸(hucieic acid)，多聚核苷酸是人体的基本组成之一。是由多个核苷酸聚合成的生物大分子、核苷酸由含氮的碱基核糖和脱氧核糖、磷脂三种分子连接而成。多聚核苷酸是一种具有多种生物学活性功能，具有增强免疫功能、抗病毒感染、抗肿瘤、抗辐射、抗氧化、抗疲劳等活性功能)。
生物活性作用：1、增强免疫功能：研究表明，无多聚核苷酸饮食或低多聚核苷酸饮食配方饲喂动物实验，其细胞免疫功能低下条件致病菌就使其感染。无多聚核苷酸饮食致使T淋巴细胞发育障碍，免疫功能低下，而没有细胞现象反应发生，同时影响T细胞依赖的体液免疫产生。动物实验显示，补充多聚核苷酸能使不同年龄的小鼠免疫器官和免疫因子活性增强，提高对疾病和病毒感染的抵抗力。临床试验数据证明，多聚核苷酸具有明显的提高免疫功能，激活免疫系统、增强抵抗力，外原性多聚核苷酸对维持免疫系统正常功能具有显著作用。
(五)脂肪酸(linolenic acid)脂肪酸是存于海藻类中的不饱和脂肪酸，是构成人体组织细胞的主要成分之一，为必需脂肪酸在人体内不能自行合成，必须从体外补充。现代药理研究表明，脂肪酸具有增强免疫功能，保护急性肺损伤、抗炎、防癌抗癌、保护肝脏、保护心血管疾病等功效作用。
生物活性作用：1、增强免疫功能：脂肪酸有助于强化免疫系统，在人体免疫系统为必需脂肪酸，能保护基因免受损害，对增强人体免疫力，提高人体抵抗力具有重要的作用。最新临床研究表明，脂肪酸可影响细胞膜结构的完整性、稳定性和流动性、细胞运动受体形成与配体的结合等，从而减少细胞因子的产生和释放，改善肝、肺脏、肠的血供和氧代谢。因此，脂肪酸在细胞水平诱导的改变较为持久，是有高效的免疫调节营养剂。另外，脂肪酸还具有保护急性肺损伤、抗炎等功能。
综上所述：本产品具有显著增强免疫功能、预防多种流感病毒感染、抗病毒(多种流感病毒和冠状病毒)抗病原体、杀菌消炎、防治病毒性肺炎、防温疫清温、清热解毒等功能。
六、实施方案：
实施例：取金蝉花多糖60-100千克、脾多肽20-60千克、蛋黄免疫球蛋白40-80千克、多聚核苷酸50-90千克、脂肪酸30-70千克、辅料为原料。将金蝉花粉碎为50目，以70％的乙醇为提取溶剂，超声功率为320W、超声温度为40℃、超声时间40min、超声完成后利用真空泵进行抽滤、滤渣2次超声萃取，合并两次滤液后用旋蒸仪浓缩、浓缩液送入蒸发器中进行真空干燥，得金蝉花多糖，再将金蝉花多糖与配方中剩余的混合、搅拌均匀，送入填充机，将原料填充于胶囊中，检验合格，包装为成品。
Claims (1)
1.防瘟疫免疫肽制作工艺，具特征为：金蝉花多糖60-100千克、脾多肽20-60千克、蛋黄免疫球蛋白40-80千克、多聚核苷酸50-90千克、脂肪酸30-70千克、辅料为原料。将金蝉花粉碎为50目，以70％的乙醇为提取溶剂，超声功率为320W、超声温度为40℃、超声时间40min、超声完成后利用真空泵进行抽滤、滤渣2次超声萃取，合并两次滤液后用旋蒸仪浓缩、浓缩液送入蒸发器中进行真空干燥，得金蝉花多糖，再将金蝉花多糖与配方中剩余的混合、搅拌均匀，送入填充机，将原料填充于胶囊中，检验合格，包装为成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010102301.0A CN111150066A (zh) | 2020-02-19 | 2020-02-19 | 防瘟疫免疫肽 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010102301.0A CN111150066A (zh) | 2020-02-19 | 2020-02-19 | 防瘟疫免疫肽 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111150066A true CN111150066A (zh) | 2020-05-15 |
Family
ID=70566214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010102301.0A Pending CN111150066A (zh) | 2020-02-19 | 2020-02-19 | 防瘟疫免疫肽 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111150066A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624187A (zh) * | 2022-12-08 | 2023-01-20 | 北京第一生物科技开发有限公司 | 牛脾肽粉在改善睡眠中的用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545920A (zh) * | 2003-12-12 | 2004-11-17 | 霖 袁 | 一种用于增强人体免疫力的食品 |
| CN104327184A (zh) * | 2014-09-28 | 2015-02-04 | 浙江省长兴艾格生物制品有限公司 | 一种蛋黄球蛋白粉的制备方法 |
| CN109985070A (zh) * | 2019-04-23 | 2019-07-09 | 江苏大学 | 一种金蝉花提取物及其在制备抗氧化药物中的应用 |
-
2020
- 2020-02-19 CN CN202010102301.0A patent/CN111150066A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545920A (zh) * | 2003-12-12 | 2004-11-17 | 霖 袁 | 一种用于增强人体免疫力的食品 |
| CN104327184A (zh) * | 2014-09-28 | 2015-02-04 | 浙江省长兴艾格生物制品有限公司 | 一种蛋黄球蛋白粉的制备方法 |
| CN109985070A (zh) * | 2019-04-23 | 2019-07-09 | 江苏大学 | 一种金蝉花提取物及其在制备抗氧化药物中的应用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624187A (zh) * | 2022-12-08 | 2023-01-20 | 北京第一生物科技开发有限公司 | 牛脾肽粉在改善睡眠中的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9662349B2 (en) | Dietary composition having mixed polysaccharides derived from lucid ganoderma, lycium barbarum and polygonatum sibiricum and method of its preparation | |
| CN101020719B (zh) | 当归复合多糖、制备工艺及用途 | |
| CN101716256B (zh) | 一种用于增强免疫的制剂 | |
| CN102755346A (zh) | 一种食用真菌复合多糖配方、制备方法及其应用 | |
| CN109757733A (zh) | 一种口服多肽粉及其制备方法和应用 | |
| CN107164446A (zh) | 鹿血肽的制备方法及其抗疲劳作用 | |
| CN111150066A (zh) | 防瘟疫免疫肽 | |
| CN102167726A (zh) | 一种利用动物血液和脾脏分离提取活性多肽和免疫核糖核酸的方法 | |
| CN113040386A (zh) | 一种帮助提高免疫力抗疲劳的复方制剂及其制备方法 | |
| CN105030812A (zh) | 一种复合真菌多糖胶囊 | |
| CN102784163A (zh) | 一种食用菌类复合多糖养生保健治疗配方及其制备方法 | |
| CN1218690A (zh) | 多肽口服液 | |
| CN1170587C (zh) | 刺槐凝集素及其用途 | |
| CN102078600B (zh) | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 | |
| CN1102066C (zh) | 一种治疗艾滋病和肿瘤的药剂及其制备方法 | |
| CN104825783B (zh) | 具有抗肿瘤活性的中药组合物及其制备方法和应用 | |
| CN1169315A (zh) | 调节免疫保健茶 | |
| CN1177598C (zh) | 治疗恶性肿瘤放化疗副反应的药物及其制备方法 | |
| CN103599125B (zh) | 抗辐射和辅助抗肿瘤药物及应用 | |
| CN101979003A (zh) | 一种抗瘤中药 | |
| JP6099360B2 (ja) | アンニンコウ抽出液の高分子画分による免疫機能強化剤 | |
| CN109432390A (zh) | 一种用于鸡传染性喉气管炎的中药肽、药物及其制备方法 | |
| TWI224006B (en) | LAK activity potentiator orginating in shiitake mushroom hyphae extract and LAK activity potentiating preparations containing the same | |
| CN100549025C (zh) | 一种胸腺五肽与匹多莫德的生成物七肽及合成方法 | |
| RU2147239C1 (ru) | Общеукрепляющее неспецифическое иммуномодулирующее средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200515 |
|
| WD01 | Invention patent application deemed withdrawn after publication |